Cutaneous melanoma: Available therapy for metastatic disease

Dermatologic Therapy

Volumn 19, Issue 1, 2006, Pages 19-25

  Tarhini, Ahmad A ^a   Garwala, Sanjiv S A ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Chemotherapy; Dacarbazine; Immunotherapy; Interleukin 2; Melanoma

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; B RAF KINASE; CANCER VACCINE; CARBOPLATIN; CISPLATIN; DACARBAZINE; GENESENSE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN; MONOCLONAL ANTIBODY LM 609; OBLIMERSEN; PACLITAXEL; PROTEIN BCL 2; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT INTERLEUKIN 2; SORAFENIB; TEMOZOLOMIDE; TUMOR ANTIGEN; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLOOD BRAIN BARRIER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; DRUG ACTIVITY; DRUG APPROVAL; DRUG DEGRADATION; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; HUMAN; HYPOTENSION; HYPOXIA; IMMUNOREGULATION; IMMUNOTHERAPY; KIDNEY FAILURE; MELANOMA; METASTASIS; NATURAL KILLER CELL; NONHUMAN; REVIEW; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; BIOLOGICAL RESPONSE MODIFIERS; CANCER VACCINES; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; INTERLEUKIN-2; MALE; MELANOMA; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SALVAGE THERAPY; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33645092920     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2005.00052.x     Document Type: Review

References (42)

1. Jemal A et al. Cancer statistics, 2005 CA Cancer J Clin 2005 55 10 30
2. Tatsumi T et al. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma J Exp Med 2002 196 619 628
3. Kirkwood JM Agarwala S Systemic cytotoxic and biologic therapy melanoma Cancer Principles and Practice of Oncology 1993 1 16
4. Crosby T et al. Systemic treatments for metastatic cutaneous melanoma Cochrane Database Syst Rev 2000 CD001215
5. Chapman PB et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma J Clin Oncol 1999 17 2745 2751
6. Stevens MF et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4 (3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine Cancer Res 1987 47 5846 5852
7. Middleton MR et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma J Clin Oncol 2000 18 158 166
8. Eton O et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial J Clin Oncol 2002 20 2045 2052
9. Atkins MB Lee S Flaherty LE Sosman JA Sondak VK Kirkwood JM A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): An ECOG-coordinated intergroup trial (abstr 2847) Proc Am Soc Clin Oncol 2003 22 708
10. Keilholz U Dacarbazine, cisplatin and IFN-α2b with or without IL-2 in advanced melanoma: Final analysis of EORTC randomized phase III trial 18951 Proc Am Soc Clin Oncol 2003
11. Del Vecchio M Multicenter phase III randomized trial of cisplatin, vindesine and dacarbazine (CVD) versus CVD plus subcutaneous (sc) interleukin-2 (IL-2) and interferon-alpha-2b (IFN) in metastatic melanoma patients (pts) Proc Am Soc Clin Oncol 2003
12. O'Day SJ et al. Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy Clin Cancer Res 2002 8 2775 2781
13. Smith KA Interleukin-2: inception, impact, implications Science 1988 240 1169 1176
14. Rosenberg SA et al. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2 J Exp Med 1985 161 1169 1188
15. Rosenberg SA et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer J Natl Cancer Inst 1993 85 622 632
16. Figlin RA et al. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma J Clin Oncol 1999 17 2521 2529
17. Dutcher JP et al. A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma J Clin Oncol 1989 7 477 485
18. Parkinson DR et al. Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study J Clin Oncol 1990 8 1650 1656
19. Rosenberg SA et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2 JAMA 1994 271 907 913
20. Atkins MB et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993 J Clin Oncol 1999 17 2105 2116
21. Atkins MB et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update Cancer J Sci Am 2000 6 Suppl. 1 S11 S14
22. Schwartzentruber DJ High-dose interleukin-2 is an intensive treatment regardless of the venue of administration Cancer J 2001 7 103 104
23. Liu K Rosenberg SA Interleukin-2-independent proliferation of human melanoma-reactive T lymphocytes transduced with an exogenous IL-2 gene is stimulation dependent J Immunother 2003 26 190 201
24. Hom SS et al. Common expression of melanoma tumor-associated antigens recognized by human tumor infiltrating lymphocytes: analysis by human lymphocyte antigen restriction J Immunother 1991 10 153 164
25. Kawakami Y et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes J Exp Med 1994 180 347 352
26. Mandelboim O et al. CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma Nature 1994 369 67 71
27. + cytotoxic T lymphocytes J Exp Med 1995 181 363 368
28. Rosenberg SA et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma Nat Med 1998 4 321 327
29. Kirkwood JM Lee S Land S et al. E1696: Final analysis of the clinical and immunological results of a multicenter ECOG phase II trial of multi-epitope peptide vaccination for stage IV melanoma with MART-1 (27-35), gp100 (209-217, 210M and tyrosinase (368-376, 370D) +/- IFN-a2b and GM-CSF. Am Soc Clin Oncol J 2004
30. Luo X et al. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors Cell 1998 94 481 490
31. Jansen B et al. Chemosensitisation of malignant melanoma by Bcl2 antisense therapy Lancet 2000 356 1728 1733
32. Millward MJ et al. Randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients (pts) with advanced malignant melanoma (MM): Analysis of long-term survival. Am Soc Clin Oncol. 2004
33. Davies H et al. Mutations of the BRAF gene in human cancer Nature 2002 417 949 954
34. Strumberg D et al. Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors Int J Clin Pharmacol Ther 2002 40 580 581
35. Strumberg D et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors J Clin Oncol 2005 23 965 972
36. Ahmad T Marais R Pyle L et al. BAY 43-9006 in patients with advanced melanoma: The Royal Marsden experience Proc Am Soc Clin Oncol Suppl 2004 22 7506
37. Flaherty K Brose M Schuchter L et al. Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma Proc Am Soc Clin Oncol Suppl 2004 22 7507
38. Srivastava PK Udono H Heat shock protein peptide complexes in cancer immunotherapy Curr Opin Immunol 1994 6 728 732
39. Rivoltini L et al. Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells J Immunol 2003 171 3467 3474
40. Belli F et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings J Clin Oncol 2002 20 4169 4180
41. Albelda SM et al. Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression Cancer Res 1990 50 6757 6764
42. Mitjans F et al. In vivo therapy of malignant melanoma by means of antagonists of αv integrins Int J Cancer 2000 87 716 723